Research

*July 2021* As research efforts prevail with encouraging therapies designed to overcome resistance to EGFR-directed therapies for patients with advanced non–small cell lung cancer (NSCLC), Sukhmani K. Padda, MD, noted that hope indeed exists for this patient populations. “There may be strategies after a certain resistance that are going to…

*July 2021* Osimertinib (Tagrisso) has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer (NSCLC), but the need for novel agents is underscored as disease progression on the agent is inevitable, according to Karen Kelly, MD. To this end, bispecific antibodies, antibody-drug conjugates (ADCs), EGF…

*July 2021* Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) in the first line setting are the key to unlocking the next wave of success in treating lung cancer, according to Jonathan W. Riess, MD, MS, associate professor of medicine at the University…

*June 2021* Data from a landmark research study shows that the biology behind “young” lung cancer – lung cancer diagnosed under the age of 40 – is different from that of the general population. The Genomics of Young Lung Cancer study, conducted by GO2 Foundation for Lung Cancer and our…

*August 2021* The CHRYSALIS Study is for adults with previously treated advanced non-small-cell lung cancer (NSCLC). The study is broken down into different parts and is specifically recruiting patients with NSCLC that have a documented primary MET Exon 14 skipping mutation. An investigational medication will be given to eligible participants…

*August 2021* Attention All Resisters! A new clinical trial finder, Medifind, is now live, which may help EGFR Resisters to quickly narrow down the many thousands of clinical trials based on information specific to us. This version includes the specific terms and keywords we would use to find an appropriate trial. So hopefully…

*June 2021* Treatment advances for patients with non–small cell lung cancer (NSCLC) who harbor HER2, EGFR, KRAS, and MET mutations have generated significant excitement and set the stage for further research aimed at generating better tolerated, more effective, and optimally sequenced treatments. Nicholas C. Rohs, MD, an assistant professor of medicine, hematology, and medical oncology at…

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor, in both treatment-naïve and osimertinib (osi)-relapsed patients (pts) with EGFRm NSCLC (Cho Ann Oncol 2020;31:S813). We present updated results of the combination in osi-relapsed pts, including an…

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung cancer (NSCLC) were first pinpointed in 2004. These mighty mutations have emerged as the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) therapies, with deletions in exon 19 and the point…

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Au has been approved in China for treatment of patients (pts)…